A new prescription combination treatment for asthma patients is now available that contains fluticasone and formoterol in a single inhaler.
The medicine is available in three strengths - two low-level types for adults and adolescents aged at least 12 years, and the strongest for adults aged 18 years and over.
The inhaler contains a colour coded dose indicator so that patients can ascertain how much medication is left in the device.
This will be the first time that a single inhaler contains a combination of fluticasone propionate (fluticasone), an inhaled corticosteroid (ICS) and formoterol fumarate (formoterol), a long-acting β2-agonist (LABA).
The fluticasone/formoterol combination inhaler is being marketed under the brand name Flutiform and is manufactured by Napp Pharmaceuticals Limited.
Stephanie Wolfe, a respiratory nurse specialist from Norfolk, said: “Data from a recent survey suggested that despite perception of good control many patients still have symptoms and a small but significant number of people are still visiting A&E.”
Ms Wolfe added: “We know from experience that regular reviews allow us to monitor a patient’s condition, educate them about effective inhaler technique and importantly ensure they receive the best possible treatments that match their individual needs.
“Choice is therefore important and we welcome new combination treatment options that may help to further achieve this.”